Jpmorgan Chase & CO Compass Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 44,464 shares of CMPX stock, worth $60,915. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,464
Previous 45,883
3.09%
Holding current value
$60,915
Previous $45,000
80.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CMPX
# of Institutions
79Shares Held
91.9MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$30.6 Million0.97% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.1MShares$15.2 Million0.04% of portfolio
-
Blackstone Inc New York, NY10MShares$13.7 Million0.09% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$9.06 Million0.0% of portfolio
-
Bio Impact Capital LLC Cambridge, MA5.64MShares$7.73 Million1.62% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $139M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...